Patient characteristics
Characteristic . | Value . |
|---|---|
| CMML, n = 119 | |
| Age, y, mean/median (range) | 69/71 (20-90) |
| Sex, male/female | 73/36 |
| WBC count | |
| Fewer than 13 × 109/L | 71 |
| More than 13 × 109/L | 42 |
| No recent Mayo WBC count | 6 |
| Cytogenetics | |
| Normal | 76 |
| Abnormal | 40 |
| Trisomy 8 | 11 |
| Loss of Y chromosome | 8 |
| Del(5q) or del(20q) | 4 |
| Other miscellaneous | 17 |
| Insufficient metaphases for analysis | 3 |
| MDS, n = 101 | |
| Refractory anemia or refractory cytopenia with multilineage dysplasia | 19 |
| Refractory anemia with ringed sideroblasts* | 51 |
| Refractory anemia with excess blasts, types I or II | 12 |
| MDS atypical or not otherwise specified | 18 |
| Other aMPD, n = 25 | |
| Idiopathic hypereosinophilic syndrome | 11 |
| Systemic mastocytosis | 8 |
| Chronic neutrophilic leukemia | 6 |
Characteristic . | Value . |
|---|---|
| CMML, n = 119 | |
| Age, y, mean/median (range) | 69/71 (20-90) |
| Sex, male/female | 73/36 |
| WBC count | |
| Fewer than 13 × 109/L | 71 |
| More than 13 × 109/L | 42 |
| No recent Mayo WBC count | 6 |
| Cytogenetics | |
| Normal | 76 |
| Abnormal | 40 |
| Trisomy 8 | 11 |
| Loss of Y chromosome | 8 |
| Del(5q) or del(20q) | 4 |
| Other miscellaneous | 17 |
| Insufficient metaphases for analysis | 3 |
| MDS, n = 101 | |
| Refractory anemia or refractory cytopenia with multilineage dysplasia | 19 |
| Refractory anemia with ringed sideroblasts* | 51 |
| Refractory anemia with excess blasts, types I or II | 12 |
| MDS atypical or not otherwise specified | 18 |
| Other aMPD, n = 25 | |
| Idiopathic hypereosinophilic syndrome | 11 |
| Systemic mastocytosis | 8 |
| Chronic neutrophilic leukemia | 6 |
WBC indicates white blood cell; CMML, chronic myelomonocytic leukemia; MDS, myelodysplastic syndromes; aMPD, atypical myeloproliferative disorder.
Series includes greater proportion of refractory anemia with ringed sideroblast cases than a typical MDS population because of inclusion of 48 samples from the Mayo Acquired Sideroblastic Anemia Project.